Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MYMD MyMD Pharmaceuticals	$0.11 +13.5%	$0.13	$1.75 ▼ $63.90	$260K	2.15	134,123 shs	43.78 million shs
NAVB Navidea Biopharmaceuticals	$0.00	$0.00	$0.00 ▼ $0.13	$50K	1.71	7,875 shs	3,000 shs
NYMX Nymox Pharmaceutical		$0.34	$0.17 ▼ $0.74	$18.10M	0.64	94,622 shs	932,700 shs
VNRX VolitionRx	$0.62	$0.69	$0.40 ▼ $0.94	$64.47M	1.26	193,792 shs	87,932 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MYMD MyMD Pharmaceuticals	0.00%	-4.16%	-11.19%	-50.61%	-94.47%
NAVB Navidea Biopharmaceuticals	0.00%	0.00%	+150.00%	-95.00%	-50.00%
NYMX Nymox Pharmaceutical	0.00%	0.00%	0.00%	0.00%	0.00%
VNRX VolitionRx	-2.65%	+0.32%	-6.40%	+33.60%	+18.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MYMD MyMD Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NYMX Nymox Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	2.4676 of 5 stars	3.5	0.0	0.0	0.0	3.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MYMD MyMD Pharmaceuticals	0.00	N/A	N/A	N/A
NAVB Navidea Biopharmaceuticals	0.00	N/A	N/A	N/A
NYMX Nymox Pharmaceutical	0.00	N/A	N/A	N/A
VNRX VolitionRx	3.00	Buy	$3.50	464.52% Upside

Current Analyst Ratings Breakdown

Latest NYMX, VNRX, MYMD, and NAVB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/10/2025	VNRX VolitionRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MYMD MyMD Pharmaceuticals	N/A	N/A	N/A	N/A	$7.21 per share	N/A
NAVB Navidea Biopharmaceuticals	$8.13K	6.16	N/A	N/A	N/A	∞
NYMX Nymox Pharmaceutical	N/A	N/A	N/A	N/A	($0.01) per share	N/A
VNRX VolitionRx	$1.31M	49.27	N/A	N/A	($0.11) per share	-5.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MYMD MyMD Pharmaceuticals	-$4M	N/A	0.00	∞	N/A	N/A	-179.05%	-108.14%	N/A
NAVB Navidea Biopharmaceuticals	-$15.18M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NYMX Nymox Pharmaceutical	-$6.58M	-$0.04	N/A	N/A	N/A	N/A	-1,589.50%	-117.25%	N/A
VNRX VolitionRx	-$35.32M	-$0.27	N/A	∞	N/A	-2,321.14%	N/A	-163.39%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MYMD MyMD Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
NYMX Nymox Pharmaceutical	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MYMD MyMD Pharmaceuticals	N/A	0.62	0.62
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A
NYMX Nymox Pharmaceutical	N/A	0.19	0.19
VNRX VolitionRx	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MYMD MyMD Pharmaceuticals	9.64%
NAVB Navidea Biopharmaceuticals	0.01%
NYMX Nymox Pharmaceutical	1.14%
VNRX VolitionRx	8.09%

Insider Ownership

Company	Insider Ownership
MYMD MyMD Pharmaceuticals	2.12%
NAVB Navidea Biopharmaceuticals	43.68%
NYMX Nymox Pharmaceutical	54.00%
VNRX VolitionRx	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MYMD MyMD Pharmaceuticals	6	2.37 million	2.32 million	Optionable
NAVB Navidea Biopharmaceuticals	10	100.08 million	56.37 million	Optionable
NYMX Nymox Pharmaceutical	3	90.51 million	41.64 million	Optionable
VNRX VolitionRx	80	103.98 million	80.80 million	Optionable

NYMX, VNRX, MYMD, and NAVB Headlines

Recent News About These Companies

VolitionRx (NYSE:VNRX) Stock Price Down 4.3% - Here's What Happened

August 9 at 4:54 AM | marketbeat.com

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update | ...

August 8, 2025 | gurufocus.com

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

August 8, 2025 | prnewswire.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 78,125 Shares of Stock

August 7, 2025 | marketbeat.com

Cameron John Reynolds Buys 78,125 Shares of VolitionRx Limited (NYSE:VNRX) Stock

August 7, 2025 | marketbeat.com

VolitionRx Limited (NYSE:VNRX) Director Acquires $50,000.00 in Stock

August 7, 2025 | insidertrades.com

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

August 4, 2025 | prnewswire.com

VolitionRx (NYSE:VNRX) Given "Buy" Rating at D. Boral Capital

July 17, 2025 | marketbeat.com

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

July 16, 2025 | prnewswire.com

VolitionRx Limited (VNRX) - Yahoo Finance

July 11, 2025 | nz.finance.yahoo.com

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

July 8, 2025 | prnewswire.com

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

June 12, 2025 | prnewswire.com

Jones Trading Initiates Coverage of VolitionRx (VNRX) with Buy Recommendation

June 11, 2025 | msn.com

VolitionRx director Guy Innes buys $10,772 in common stock

June 5, 2025 | investing.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 20,000 Shares of Stock

June 5, 2025 | insidertrades.com

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

June 4, 2025 | prnewswire.com

VolitionRX shares hold as Benchmark maintains rating

May 21, 2025 | uk.investing.com

VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript

May 20, 2025 | msn.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Insider Acquires 50,000 Shares of Stock

May 20, 2025 | insidertrades.com

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 19, 2025 | prnewswire.com

VolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advances

May 16, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NYMX, VNRX, MYMD, and NAVB Company Descriptions

MyMD Pharmaceuticals NASDAQ:MYMD

$0.11 +0.01 (+13.53%)

As of 08/11/2025

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Navidea Biopharmaceuticals NYSE:NAVB

$0.0005 0.00 (0.00%)

As of 02:06 PM Eastern

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Nymox Pharmaceutical NASDAQ:NYMX

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.

VolitionRx NYSE:VNRX

$0.62 0.00 (0.00%)

Closing price 03:58 PM Eastern

Extended Trading

$0.62 +0.00 (+0.65%)

As of 06:53 PM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time